(Q34344786)

1 August 2017

1 reference

title

Current and investigational antiobesity agents and obesity therapeutic treatment targets (English)

1 reference

1 August 2017

0 references

Harold E Bays

1

1 reference

1 August 2017

publication date

1 August 2004

1 reference

1 August 2017

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

8

1 reference

1 August 2017

page(s)

1197-1211

1 reference

Prevalence and Trends in Obesity Among US Adults, 1999-2000

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Assessment of the obese patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Anti-obesity drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Thermogenic effects of sibutramine and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effects of dietary modification and treatment of obesity. Emphasis on improving vascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Behavioral treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Hyperglycemia from olanzapine treatment in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The therapeutic potential of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Obesity and the regulation of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Signals that regulate food intake and energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Clinical potentials of neuropeptide Y family of hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The role of NPY in metabolic homeostasis: implications for obesity therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

21 January 2018

Novel anti-obesity drugs

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

21 January 2018

The genetics of obesity.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Leptin and insulin action in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The source of cerebral insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The ins and outs of leptin receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Control of food intake via leptin receptors in the hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The p38 signal transduction pathway: activation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Brain insulin and feeding: a bi-directional communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effect of acarbose on weight maintenance after dietary weight loss in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

CCK1R agonists: a promising target for the pharmacological treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The management of the obese diabetic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Gut hormone PYY(3-36) physiologically inhibits food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Human uncoupling protein-3 and obesity: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Adiponectin: a regulator of energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Consumption of an oil composed of medium chain triacyglycerols, phytosterols, and N-3 fatty acids improves cardiovascular risk profile in overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Medium-chain oil reduces fat mass and down-regulates expression of adipogenic genes in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Medium-chain Fatty acids attenuate agonist-stimulated lipolysis, mimicking the effects of starvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Acarviosine-simmondsin, a Novel Compound Obtained from Acarviosine-glucose and Simmondsin byThermusMaltogenic Amylase and Itsin vivoEffect on Food Intake and Hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effects of growth hormone administration in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

The role of dehydroepiandrosterone in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Obesity and pharmacologic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Consensus development conference on antipsychotic drugs and obesity and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Risperidone in Prader-Willi syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

31 March 2020

Obesity and dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

[PPAR gamma agonist and antagonist]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Amylin as a Neuroendocrine Hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Consumption of a functional oil rich in phytosterols and medium-chain triglyceride oil improves plasma lipid profiles in men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

A succulent cure to end obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Acute postprandial gastrointestinal and metabolic effects of wheat amylase inhibitor (WAI) in normal, obese, and diabetic humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

Is dehydroepiandrosterone an antiobesity agent?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

11beta-hydroxysteroid dehydrogenase type 1 in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

31 March 2020

The genetics of obesity

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.151

31 March 2020

Identifiers

DOI

10.1038/OBY.2004.151

1 reference

1 August 2017

1 reference